RNAC Q3 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$452,000+16.8% YoY

Gross Profit

-$12M-2731.2% margin

Operating Income

-$21M-4660.6% margin

Net Income

-$36M-7942.9% margin

EPS (Diluted)

$-1.38

QoQ Revenue Growth

+51.7%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$373M

Total Liabilities

$409M

Stockholders' Equity

-$36M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$452,000	$387,000	+16.8%
Gross Profit	-$12M	$387,000	-3289.9%
Operating Income	-$21M	-$18M	-19.9%
Net Income	-$36M	-$24M	-48.5%